A Coup for Gen-Probe
Executive SummaryChiron and Gen-Probe have entered into a strategic alliance which gives Chiron access to Gen-Probe's nucleic acid technologies and Gen-Probe gets rights to use HCV and other proprietary Chiron technology in manufacturing assays. Chiron will be selling Gen-Probe instruments to blood banks and clinical labs. Blood banks are starting to get interested in DNA screening for some major viral infections like HIV and HCV, because the technique is more sensitive and specific. The deal is a coup for Gen-Probe, because it gets rights to one of most coveted patents in diagnostics and it broadens Chiron's DNA platform beyond the disappointing bDNA.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.